	US 12,448,419 B2
	Methods and compositions for treating inflammation
Pedro Santamaria, Calgary (CA)
Assigned to UTI Limited Partnership, Calgary (CA)
Filed by UTI Limited Partnership, Calgary (CA)
Filed on Jan. 20, 2021, as Appl. No. 17/153,212.
Application 17/153,212 is a continuation of application No. 13/842,302, filed on Mar. 15, 2013, granted, now 10,988,516.
Claims priority of provisional application 61/615,743, filed on Mar. 26, 2012.
Prior Publication US 2021/0230237 A1, Jul. 29, 2021
Int. Cl. A61K 39/385 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 47/69 (2017.01); C07K 14/195 (2006.01); C07K 14/47 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 39/0008 (2013.01); A61K 39/0216 (2013.01); A61K 47/6923 (2017.08); C07K 14/195 (2013.01); A61K 2039/55555 (2013.01); Y10T 428/2982 (2015.01)]

18 Claims

1. A method for treating inflammation in the gastrointestinal (GI) tract of a patient in need thereof comprising parenterally administering to the patient an effective amount of a nanoparticle composition, wherein the composition does not comprise an adjuvant, wherein the composition comprises a plurality of nanoparticle cores, each nanoparticle core coupled to a plurality of peptide antigen-MHC complexes, wherein:

the peptide antigen comprises a peptide having at least 80% identity to a peptide sequence chosen from SEQ ID NO:4 to SEQ ID NO:8 across the entire length;

the nanoparticle core has a diameter from about 1 nm to about 100 nm; and

the ratio of peptide antigen-MHC complexes per nanoparticle core is from about 10:1 to about 1000:1; and

the peptide antigen is a T cell epitope.